Improving access to clinical trials
Clinical trials are the single best way to turn advances in science into patient benefits. The ICR has a vision that a suitable trial should be made available for every person with cancer who wants to be part of one.
Expanding trial access – ICR report
Our 2021 report, Clinical trials in cancer, reveals the impact of the Covid-19 pandemic on cancer trials and highlights longstanding barriers to expanding clinical trial access to more people with cancer. But Covid-19 also offers clues to a recovery that can get new treatments to cancer patients more quickly.
News: Cancer trial recruitment drops by 60 per cent during pandemic
The number of cancer patients entering clinical trials has plummeted during the pandemic – denying many thousands the latest treatment options and delaying drug development. Here, cancer experts set out their findings about the barriers to carrying out clinical trials in the UK and proposals for boosting participation.Latest ICR News
Why is animal research still necessary to defeat cancer?
In this feature, cancer scientists and animal research experts across The Institute of Cancer Research, London, discuss why breakthroughs gained by studying whole-body systems in animals are essential in understanding how cancer develops and behaves within a whole organism, and how to treat it effectively.
ICR scientists support promising new immunotherapy trial for advanced ovarian cancer
Scientists at The Institute of Cancer Research, London, are supporting an international clinical trial of a promising new immunotherapy treatment for advanced ovarian cancer.
New study reveals key enzyme as hidden driver of cancer stress responses
An important study has uncovered an unexpected molecular player that helps make cancer cells stress-resilient, thereby promoting the survival, growth and progression of cancer.
Scientists discover new avenue for treating an aggressive form of breast cancer
A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research by scientists at The Institute of Cancer Research, London